PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
1.17M
Worse than SGMO's estimated revenue of 109.54M.
-234.73K
Better than SGMO's estimated ebitda of -160.70M.
-1.16
Better than SGMO's estimated eps of -1.32.
-30.77M
Better than SGMO's estimated net income of -179.04M.
-234.73K
Better than SGMO's estimated ebit of -184.49M.
43.49M
Better than SGMO's estimated sg&a expense of 64.11M.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-21.77M
Better than SGMO's ebitda of -123.87M.
100.00%
Better than SGMO's ebitda margin of -104.80%.
-22.21M
Better than SGMO's ebit of -129.55M.
100.00%
Better than SGMO's ebit margin of -109.61%.
447.00K
Better than SGMO's depreciation of 5.68M.
63.56M
Worse than SGMO's total cash of 691.95M.
100.00%
Worse than SGMO's cash as percentage of revenue of 585.45%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than SGMO's receivables as percentage of revenue of 5.30%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than SGMO's inventories as percentage of revenue of -42.75%.
4.34M
Better than SGMO's accounts payable of 12.55M.
100.00%
Worse than SGMO's payables as percentage of revenue of 10.62%.
-253.00K
Worse than SGMO's capital expenditure of -14.71M.
100.00%
Worse than SGMO's capex as percentage of revenue of -12.45%.
4.99%
Better than SGMO's weighted average cost of capital (wacc) of 9.14%.
5.02%
Better than SGMO's cost of equity of 9.58%.
4.08%
Better than SGMO's cost of debt of 4.40%.
-0.23
Better than SGMO's beta of 1.10.
30.07M
Better than SGMO's diluted shares outstanding of 174.44M.
1.57M
Better than SGMO's total debt of 38.10M.
49.31M
Worse than SGMO's total equity of 409.94M.
50.89M
Worse than SGMO's total capital of 448.05M.
3.09%
Better than SGMO's debt weighting of 8.50%.
96.91%
Better than SGMO's equity weighting of 91.50%.
-22.04M
Better than SGMO's ebiat of -129.92M.
-17.50M
Better than SGMO's unlevered free cash flow of -73.72M.
2.00%
Equal to SGMO's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than SGMO's net debt of -7.10M.
71.33M
Better than SGMO's equity value of -4.28B.
2.37
Better than SGMO's equity value per share of -24.51.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.